Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Can evenamide become the first real breakthrough for treatment-resistant schizophrenia?
Newron Pharmaceuticals reveals evenamide data at WCBP 2025, showcasing new hope for treatment-resistant schizophrenia through glutamate modulation.
Can Avacta’s peptide drug conjugates rival ADCs? The next chapter in targeted cancer delivery
Avacta’s peptide drug conjugates could change how we deliver cancer drugs. Find out how they compare to ADCs and what’s next for the UK biotech’s platform.
Can pridopidine finally change the trajectory of Huntington’s disease progression?
Can pridopidine change the course of Huntington’s disease? Explore key data from the Nature Medicine study and what’s next for Prilenia’s regulatory path.
How Merck’s Keytruda became a global immunotherapy benchmark in cancer treatment
Explore Keytruda’s journey from early PD-1 research to global immunotherapy dominance, with clinical, regulatory, and innovation context shaping cancer care in 2025.
Who’s funding the psychedelic revolution in pharma? Follow the money from PIPEs to Big Pharma M&A
Psychedelic biotech is evolving—from VC hype to pharma buyouts. Discover who’s funding the next generation of depression treatments in 2025.
What happened to Moderna’s combo COVID–flu–RSV vaccine—and is it still in the race for 2026?
Moderna’s combo COVID–flu vaccine has been delayed to 2026 after FDA feedback. Find out what caused the setback and whether the mRNA-1083 shot can still launch next year.
Why is Evernorth investing $3.5bn in shields health solutions—and why now?
Find out how Evernorth’s $3.5B investment in Shields Health Solutions could reshape hospital-based specialty pharmacy care across the U.S.
Cytokinetics stock skyrockets 40% as ESC 2025 data positions aficamten to challenge beta-blockers in HCM
Cytokinetics shares surged 40% after new ESC 2025 data showed aficamten's superiority to metoprolol in HCM. Is FDA approval now inevitable?
United Therapeutics stock soars 34% after TETON-2 IPF trial win: Can Tyvaso reshape the fibrosis market?
United Therapeutics jumps 34% on TETON-2 IPF trial success. Find out how this could reshape the pulmonary fibrosis treatment landscape.
Why the MediSpend–RLDatix merger could reset benchmarks in global pharma compliance software
MediSpend and RLDatix Life Sciences have merged to create a full-stack SaaS compliance giant for pharma and biotech. Discover what this means for the sector.